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Purpose: To date the standard nosology and prognostic schemes for myeloid neoplasms have been based
on morphologic and cytogenetic criteria. We sought to test the hypothesis that a comprehensive, unbi-
ased analysis of somatic mutations may allow for an improved classification of these diseases to predict
outcome (overall survival).
Experimental design: We performed whole-exome sequencing (WES) of 274 myeloid neoplasms, includ-
ing myelodysplastic syndrome (MDS, N = 75), myelodysplastic/myeloproliferative neoplasia (MDS/MPN,
N = 33), and acute myeloid leukemia (AML, N = 22), augmenting the resulting mutational data with public
WES results from AML (N = 144). We fit random survival forests (RSFs) to the patient survival and clini-
cal/cytogenetic data, with and without gene mutation information, to build prognostic classifiers. A tar-
geted sequencing assay was used to sequence predictor genes in an independent cohort of 507 patients,
whose accompanying data were used to evaluate performance of the risk classifiers.
Results: We show that gene mutations modify the impact of standard clinical variables on patient out-
come, and therefore their incorporation hones the accuracy of prediction. The mutation-based classifica-
tion scheme robustly predicted patient outcome in the validation set (log rank P ¼ 6:77 1021; poor
prognosis vs. good prognosis categories HR 10.4, 95% CI 3.21–33.6). The RSF-based approach also com-
pares favorably with recently-published efforts to incorporate mutational information for MDS prognosis.
Conclusion: The results presented here support the inclusion of mutational information in prognostic
classification of myeloid malignancies. Our classification scheme is implemented in a publicly available
web-based tool (http://myeloid-risk.case.edu/).
 2015 Elsevier Inc. All rights reserved.1. Introduction
Traditional classification of myeloid neoplasms relies heavily on
morphologic and cytogenetic features to define major sub-entities
and risk categories. The goals of nosologic schemes are to define
disease by the most likely outcomes, biologic behavior, and
therapy responses. Despite constant improvement, classical and
current categorization schemes [10,11,21,3] suffer from hetero-
geneity within classes and poor distinction between classes. More-
over, morphology-defined sub-entities may not reflect underlyingdisease severity due to redundancies in the function of various
molecular defects as well as phenocopies.
Recent technological advances facilitate new levels of under-
standing of the molecular pathogenesis of cancer in general, and
specifically in myeloid neoplasms where progress has been partic-
ularly rapid. Whole-exome sequencing (WES) allows detection of
nearly all amino acid coding changes in an individual genome
[20,17,25], revealing the diversity of mutations and the complexity
of mutational patterns, which likely explains a portion of clinical
heterogeneity. The technology therefore opens the door to incorpo-
rating somatic mutations into diagnostic and prognostic applica-
tions, with the potential to augment current schemes.
In general, the most common statistical approach for identify-
ing patient features that have an impact on outcome is Cox regres-
sion applied to right-censored data. However, challenges arise
when using gene mutations as classifying features in the Cox
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will collectively carry mutations in thousands of distinct genes.
The Cox proportional hazards assumption may not hold, and
non-linear effects and interactions are difficult to capture without
severe risk of overfitting, especially with very large numbers of
classifying features. The problems are particularly acute when rela-
tionships among mutations, patient survival, and other variables
are complex. For example, NPM1 mutations have been associated
with improved AML patient outcome in the absence of FLT3 inter-
nal tandem duplication (FLT3-ITD) [5], and also in the presence of
IDH1 or IDH2 [30]. On the other hand, adverse prognosis has been
reported [29] for AML patients with IDH1 or IDH2 mutations and
absence of FLT3-ITD. These types of complex dependencies cannot
be captured by linear regression models such as the Cox model
unless interaction terms are included. Power to detect interactions
in this way would require much larger sample sizes than are typ-
ically available.
As an alternative approach we have adopted random survival
forests (RSFs) to integrate gene mutations into a risk classifier of
myeloid malignancy patients. An extension of random forests [4],
RSFs are specifically designed for survival data. Briefly, the proce-
dure constructs hundreds to thousands of decision trees, each of
which uses a random subset of predictors (clinical features and/
or mutation status in our case) to iteratively split the patient set
into subsets with similar survival. The result of the procedure is
an ensemble forest that collectively assigns each patient a pre-
dicted mortality. RSFs have the advantage of being able to handle
non-linear effects and interactions automatically, owing to the
complex multiple-decision-tree structure of the forest. Overfitting
is minimized by randomizing the samples and variables used for
each tree and split, respectively. In addition, the importance of
the classifying variables may be assessed using the ‘‘minimal depth
of maximal subtree” metric [14].
The RSF methodology is particularly well-suited to studies
involving large numbers of classifying variables, as is the case with
data produced by genomic biotechnologies. Since their introduc-
tion, RSFs have been applied to various human diseases. In cancer,
researchers have used the approach to assess risk from genomic
and non-genomic data alike. Outcomes for colon [22] and thyroid
[1] cancer patients have been predicted by applying RSFs to data
from large non-genomic databases, while genomic/proteomic data
of various types were recently used to develop RSF-based predic-
tors of outcome in 12 different tumor types [39]. In leukemias, RSFs
were used to predict survival from DNA methylation data in AML
[37] and from gene expression data in pediatric T-cell acute lym-
phoblastic leukemia [35].
Here, we performed WES on myeloid neoplasms of various
types to test the hypothesis that a comprehensive analysis of
somatic mutations may allow for an enhanced classification of
these diseases, facilitating separation of the entities based on out-
come (overall survival). We postulate that mutational features
reflect the distinct pathogenesis of individual subtypes because
of their direct foundation in molecular defects. We incorporate
both gene mutation information from WES and more standard
clinical variables such as cytogenetics, diagnoses, and morpholog-
ical features. Our patient cohort comprises hundreds of individuals
diagnosed with myelodysplastic/myeloproliferative neoplasms
(MDS/MPN), myelodysplastic syndrome (MDS), or acute myeloid
leukemia (AML). Our goals were to use RSFs (i) construct risk clas-
sifiers based on mutations and clinical features; (ii) assess the per-
formance of the classifiers on an independent validation set; (iii)
determine the improvement in prognostic accuracy gained by
incorporating the mutation data in addition to the standard vari-
ables; and (iv) compare the performance of the RSF-based
approach with extant MDS-specific prognostic schemes. Our
mutation-based risk classifier is distributed as a publicly availableweb-based tool, allowing the user to input clinical variable values
andmutational status of relevant genes, producing the correspond-
ing risk category.2. Materials and methods
2.1. Patient cohorts
All samples were collected after written informed consent was
obtained. For the training (WES) cohort, paired tumor (bone mar-
row aspirate) and normal (CD3+ T-cells) DNA was obtained from
Cleveland Clinic patients diagnosed with MDS, MDS/MPN, and
AML. Data from these patients were augmented with clinical and
WES data for AML patients from the Cancer Genome Atlas (TCGA)
[18]. For the validation (targeted sequencing) set, tumor DNA
(from bone marrow aspirate or peripheral blood) was subjected
to targeted gene enrichment and deep-sequenced. Cytogenetic
anomalies for all samples were called using FISH or single nucleo-
tide polymorphism (SNP) arrays. SNP array analysis was performed
using Affymetrix 250K and 6.0 platforms (Affymetrix, Santa Clara,
CA) according to the standard protocols, followed by copy number
analysis using CNAG (v3.0) [26] or Genotyping Console (Affyme-
trix). Patients positive for the t(15;17) translocation or for chromo-
somal lesions affecting the core binding factor transcription
complex were omitted from downstream analysis. Malignancies
with these characteristics are considered to be separate entities,
are already known to be driven by very specific rearrangements,
and are associated with much more favorable outcomes than other
forms of myeloid malignancies [41]. Patient characteristics for both
the training and validation cohorts are shown in Table 1.
2.2. Whole-exome sequencing and mutation calling
For WES, total genomic DNA was enriched for approximately
50 Mb of protein coding sequences by liquid phase hybridization
using SureSelect version 4 (Agilent), followed by massively parallel
sequencing with the HiSeq 2000 (Illumina), according to the man-
ufacturers’ protocols. Sequence data was aligned using BWA [19]
and candidate variants were detected with the GATK pipeline
[24] (Supplementary Fig. S1). Somatic protein-altering and splice
site mutations were identified using Genomon (http://genomon.
hgc.jp/exome/en/index.html). TCGA patient mutation calling was
performed as previously described [18].
2.3. Target assay and sequencing for classifier validation
A TruSeq (Illumina) custom enrichment kit was designed to
include the coding regions of genes with mutations that were
deemed likely to influence patient outcome. The kit was used to
extract these genomic regions from the validation cohort DNA for
sequencing on the MiSeq (Illumina), and mutations were called
with the GATK pipeline [24] (Supplementary Fig. S1).
2.4. Statistical analysis
The probability of m patients in our WES cohort harboring a
mutation in a gene with patient population mutation frequency f
was calculated as P(X =m), where X is distributed as a Binomial
(274,f) random variable (since our cohort size is 274). Survival
analysis was conducted using R [31] version 3.0.2, with the sur-
vival [33] and randomForestSRC [13] packages. Mosaic plots were
created in R using the mosaicplot function, and Kendall’s s com-
puted using the cor.test function with method = ‘‘Kendall”. Associ-
ation between prognostic group and binary variables (mutation
and cytogenetic status) was assessed using Fisher’s exact test on
Table 1
Patient characteristics (training and validation cohorts). IQR denotes interquartile
range.
Training cohort Validation cohort
Patient count 274 507
MDS 75 (27.4%) 236 (46.6%)
Histologically high risk 26 (34.7%) 95 (40.3%)
Histologically low risk 49 (65.3%) 141 (59.7%)
IPSS high risk 9 (11.7%) 12 (5.1%)
IPSS intermediate-2 20 (26.0%) 39 (16.7%)
IPSS intermediate-1 30 (39.0%) 93 (39.7%)
IPSS low risk 18 (23.3%) 90 (38.5%)
MDS/MPN 33 (12.0%) 97 (19.1%)
AML 166 (60.6%) 174 (34.3%)
Clinical measures (median ± IQR)
Hemoglobin (g/dL) 9.8 ± 1.7 9.8 ± 2.4
Bone marrow blasts 8.5 ± 43.3 4.0 ± 18.0
Platelets (109/L) 64.0 ± 90.8 74.0 ± 122.0
Absolute neutrophil
count (109/L)
2.0 ± 3.9 2.15 ± 4.0
Cytogenetics
Normal 105 (38.3%) 262 (51.7%)
3q- 6 (2.2%) 12 (2.4%)
inv(3) 1 (0.36%) 3 (0.59%)
t(3q) 0 (0.0%) 1 (0.20%)
5q- 43 (15.7%) 56 (11.0%)
7- 16 (5.8%) 49 (9.7%)
7q- 27 (9.9%) 41 (8.1%)
Trisomy 8 27 (9.9%) 56 (11.0%)
t(9;11) 2 (0.73%) 1 (0.20%)
11q- 2 (0.72%) 14 (2.8%)
12p- 10 (3.6%) 14 (2.8%)
inv(17q) 1 (0.36%) 4 (0.79%)
Trisomy 19 2 (0.73%) 10 (2.0%)
20q- 12 (4.4%) 41 (8.1%)
Y- 4 (1.5%) 14 (2.8%)
Complex 20 (7.3%) 27 (5.3%)
Demographics
Age (mean ± sd) 61.9 ± 15.3 66.1 ± 12.9
Gender 61% male 63% male
Outcome
Alive at last followup 28% 31%
Time to death (months,
median ± IQR)
10.1 ± 14.4 7.6 ± 12.5
RSFclin+mut prognostic categories
Poor 28% 9%
Intermediate Poor 29% 46%
Intermediate Good 25% 42%
Good 18% 3%
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pared using the non-parametric Wilcoxon test.
To test interactions between gene mutations and clinical fea-
tures, we fit a Cox proportional hazards model, including gene
mutation, the clinical feature, and interaction terms. The P-values
reported correspond to the interaction terms. In the case of bone
marrow blasts, hazard ratios and their confidence intervals are
shown separately for patients with and without the relevant gene
mutation.2.5. Constructing the risk score from RSF
The R package randomForestSRC was used to construct a RSF
from the data. FLT3mutations were separately classified as internal
tandem duplications (FLT3-ITD) or tyrosine kinase domain muta-
tions (FLT3-TKD). Cytogenetic lesion status was encoded as a bin-
ary variable (presence/absence) for del(11q), del(12p), del(20q),
del(3q), del(5q), del(7), del(7q), del(Y), inv(17q), inv(3), t(3q), t
(9;11), trisomy 19, trisomy 8, and complex. Numerical values for
absolute neutrophil count, bone marrow blast percentage, hemo-globin, and platelets were stratified into categories corresponding
to those in [11]. Each stratum was coded as a binary indicator vari-
able. Indicator values for missing numeric variables were set to
zero. RSFclin was constructed using only clinical variables, while
RSFclin+mut additionally incorporated gene mutation status. The
ensemble mortality output by the RSF was used as the risk score
for each patient.2.6. Stratifying risk score to obtain prognostic categories
Given a risk score for each individual, categories were assigned
by constructing a survival tree [9] using the R package rpart with
default parameters. Briefly, at each split, the tree assigns the score
threshold that optimally separates the patients by overall survival.
Splitting is recursively performed until there are too few patients
to meaningfully split based on risk score. The leaf nodes in the final
tree determine the class assignments, which are therefore deter-
mined by risk score thresholds.3. Results
3.1. Training and validation cohorts
Our training cohort comprised 274 myeloid malignancy
patients, including patients diagnosed with MDS (N = 75), MDS/
MPN (N = 33), and AML (N = 22), augmented with 144 AML
patients from TCGA [18]. The validation set comprised 507 myeloid
malignancy patients (N = 236, 97, and 174 for MDS, MDS/MPN, and
AML, respectively). Patient characteristics are summarized in
Table 1. We reasoned that a pan-diagnosis classifier would perform
well provided it was trained on a cohort with substantial represen-
tation from all three diagnoses. Furthermore, using the diagnoses
themselves as input variables will account for any diagnosis-
specific effects. Our strategy was to build two different RSFs on
the training set data, the first using clinical data only and the sec-
ond also incorporating mutation data. Both RSF classifiers were
then tested on the validation set (Fig. 1; see Section 2). This strat-
egy allows us to assess the additional prognostic accuracy con-
ferred by incorporating gene mutations.3.2. Random forest classification using standard clinical variables
We first built a RSF using the clinical variables – cytogenetics,
diagnoses, absolute neutrophil count, bone marrow blasts, hemo-
globin, and platelets – shown in Table 1, to obtain a risk classifica-
tion termed RSFclin (Supplementary Fig. S2). Classifying features
comprise both continuous (e.g. hemoglobin) and binary (cytoge-
netic features) variables. The variable importance measure in the
randomForestSRC package is known to unfairly favor continuous
variables over categorical ones [14]. We therefore deliberately
treated all classifying features as binary variables as this allows
all variables to be considered equally. The continuous variables
were stratified by well-established clinically relevant thresholds
[11].
As expected, the RSFclin risk categories corresponded closely
with actual overall survival in the training set (P ¼ 5:34 1047;
Fig. 2A). The classifier remained robust when applied to the valida-
tion set as a whole (P ¼ 8:32 1012; Poor vs. Good prognosis cat-
egories hazard ratio 3.56; Fig. 2B), supporting the use of the RSF as
an alternative approach to assessing patient risk from standard
myeloid malignancy clinical features. The classifier was somewhat
predictive within specific diagnoses (P ¼ 6:6 103, 0.0369, and
5:01 103 for MDS, MDS/MPN, and AML, respectively; Supple-
mentary Fig. S3), but left room for improvement. We next sought
Fig. 1. Conceptual overview of prognostic classifier construction and validation. The random survival forest is built on the training cohort, incorporating clinical variables (for
RSFclin) or clinical variables and WES data (for RSFclin+mut). The resulting ensemble mortality values are stratified by a survival tree to determine categories. The same forest
and stratifying thresholds are then applied to the validation cohort and performance is assessed.
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improve accuracy in patient risk classification.3.3. Whole-exome sequencing shows a heterogeneous mutational
spectrum across patients
WES of our training cohort of 274 myeloid malignancy patients
was followed by a bioanalytic and validation pipeline (Supplemen-
tary Fig. S1, Supplementary Table S1; see Section 2). Overall, 5548
genes had a validated non-synonymous or splice site mutation in
at least one patient. The median number of mutations per patient
was 14, and 97% carried at least one mutation. Four genes –
DNMT3A, FLT3, NPM1, and TET2 – harbored mutations in more than
10% of patients. Given the cohort size of 274, theoretical expecta-
tion (Supplementary Fig. S4) is that a gene with a general patient
population mutation frequency of 10% would be mutated in
approximately 27 patients (95% CI 18–37) in our cohort, while
those with frequency 3% would be expected to be mutated in 8
patients (95% CI 3–14). It is unlikely that genes mutated at fre-
quencies lower than these would have detectable impact on
patient outcome. Therefore, we restricted the feature space to the
mutational status of the 71 genes mutated in at least five patient
samples (training cohort shown in Supplementary Fig. S5, valida-
tion cohort shown in Supplementary Fig. S6).3.4. Incorporating mutational information into the risk classifier
To select the gene mutations most associated with patient out-
come, we first applied the RSF variable selection procedure to the
clinical variables and 71 gene mutations, ranking these classifying
features in terms of importance (Supplementary Fig. S7). As down-
stream classifying mutational features, we only included genes
ranked among the most important, as well as those previously
reported as significant in myeloid malignancies [18,28,12] (Supple-
mentary Table S2). These 30 classifying genes, along with the clin-
ical variables, served as input to construct the second RSF classifier,
termed RSFclin+mut (Supplementary Fig. S8). RSFclin+mut hasimproved performance over RSFclin on the training cohort
(P ¼ 1:05 1070; Fig. 2C).
To apply RSFclin+mut to the validation cohort, we designed a cus-
tom enrichment panel that included the 30 classifying genes. The
enrichment products for each gene were deep-sequenced, and each
patient was annotated with presence or absence of mutation in
each gene. These values, as well as the clinical variable values,
were run through the RSFclin+mut classifier for each patient. The risk
classifier was very predictive of actual patient outcome in the val-
idation cohort (P ¼ 6:77 1021; Fig. 2D and E). The two-year sur-
vival rates for the patients assigned to the good, intermediate good,
intermediate poor, and poor prognostic categories were 64%, 47%,
23%, and 6%, respectively. The classifier’s performance remained
robust even within individual diagnoses (P = 3.41  107,
3.4  105, and 4.28  105, respectively within MDS, MDS/MPN,
and AML; Supplementary Fig. S9).
3.5. Gene mutations modify the effects of clinical variables
Closer examination of the relationships between the risk groups
and classifying variables gives a complex picture of the variables’
impact on patient outcome (Supplementary Fig. S10; Supplemen-
tary Fig. S11). The improved performance of RSFclin+mut over RSFclin
implies that the mutational information provides additional prog-
nostic information not available from clinical variables, and there-
fore is able to modify risk categories assigned by clinical variables
to make predictions more accurate. On a univariate level, muta-
tions in six genes – DNMT3A, EZH2, FLT3-TKD, RUNX1, SF3B1, and
TP53 – are strongly associated with RSF-determined mortality
(Supplementary Fig. S11; Supplementary Table S2). Mutations in
all of these genes, save SF3B1, are associated with poorer outcomes.
Individuals with wild-type SF3B1 collectively have higher mortal-
ity, suggesting prognostic benefit from SF3B1 mutation. Individual
patient risk categories assigned by RSFclin+mut and RSFclin show
some concordance (Kendall s = 0.502; Fig. 3A), but inclusion of
the mutational information tunes risk assignment in a way that
yields clear improvement in prognostic accuracy (Fig. 3B). We next
investigated the reasons for this improvement by examining the
Fig. 2. Kaplan–Meier curves for random survival survival forest classifiers. (A) RSFclin applied to the training set. (B) RSFclin applied to the validation set. (C) RSFclin+mut applied
to the training set. (D) RSFclin+mut applied to the validation set. (E) Hazard ratio estimates and median two-year survival for RSFclin and RSFclin+mut categories in validation set.
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on patient outcome.
Analysis of statistical interactions between mutations and clin-
ical variables show that specific gene mutations appear to exacer-
bate the prognostic impact of certain clinical variables. These risk
modifications likely partially explain the enhanced prognostic
accuracy conferred by mutational information. In particular, the
presence of NRAS or PHF6 mutation in combination with trisomy
(8) is associated with a particularly poor prognosis (interactionP = 0.002 and 0.02, respectively; Fig. 4A). Mutations in CBL or
TP53 appear to worsen the impact of elevated bone marrow blasts
(interaction P = 0.09 and 0.002, respectively; Fig. 4B).
3.6. Comparison with existing prognostic classifiers
A number of recent studies have incorporated mutational infor-
mation for MDS patient risk classification. The studies use either
both clinical and mutational data [28,38] or only mutational data
Fig. 3. Gene mutations modify RSFclin-derived patient prognosis. (A) Mosaic plot comparing RSFclin and RSFclin+mut in total cohort (training and validation). The rectangle areas
indicate relative numbers of patients in each prognostic category intersection. Shading indicates patients whose prognostic category improved (black) or worsened (gray)
from RSFclin to RSFclin+mut (B) Kaplan–Meier curves for patients whose risk category changed between RSFclin and RSFclin+mut classifiers. Here the columns correspond to the RSF
classification, and are each divided into four blocks, ordered according to RSFclin+mut classification (from Poor at bottom to Good at top). The dashed lines indicate that there
are no patients in the corresponding prognostic category intersection.
Fig. 4. Statistical interactions between gene mutations and clinical variables. (A) Kaplan–Meier curves showing interactions between gene mutations and cytogenetic
features. In both cases, mutations in the gene (NRAS and PHF6) combined with trisomy(8) are associated with significantly worse prognosis. (B) Hazard ratios and confidence
intervals showing interactions between gene mutations and bone marrow blasts. Hazard ratios are shown overall (top of the panel), as well as for patients stratified by gene
mutation status (positive and negative for mutation).
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Fig. 5. Kaplan–Meier curves for six MDS prognostic classifiers. All were applied to the WES cohort. RSF⁄clin+mut was trained on the targeted sequencing cohort.
110 M. Ruffalo et al. / Journal of Biomedical Informatics 58 (2015) 104–113
M. Ruffalo et al. / Journal of Biomedical Informatics 58 (2015) 104–113 111[2,38]. Two of the classifiers [28,38] incorporate mutational status
of genes that were not included as part of our validation cohort tar-
geted sequencing assay. Therefore, we assess prognostic accuracy
for all classification schemes using our WES (training) cohort, since
all schemes’ classifying genes are assayed. To ensure a fair compar-
ison with our RSF approach, we exchange our training and valida-
tion cohorts from above, training a RSF on the targeted sequencing
cohort to assess its performance on the WES cohort. The resulting
RSF classifier, termed RSF⁄clin+mut is restricted to MDS patients. The
performance of RSF⁄clin+mut surpasses that of the other methods,
and is comparable to that of IPSS-R. [11] (Fig. 5; Supplementary
Fig. S12).3.7. Implementation and public availability
One disadvantage of a RSF classifier is the lack of transparency.
Methods that use smaller numbers of classifying variables may be
represented as scoring systems that can be communicated as a
look-up table [38] or as lists of genes [28], facilitating biological
interpretation. The RSFs presented here involved thousands of
decision trees that collectively yield the mortality score. Straight-
forward presentation of the classification criteria is therefore chal-
lenging. Nonetheless, the risk assignments of RSFclin+mut are
deterministic in the sense that a patient’s combination of clinical
parameters and mutation status in the 30 genes uniquely determi-
nes risk category. We have implemented the risk assignment as a
web-based tool (http://myeloid-risk.case.edu/) that allows the user
to input the value of each classifying variable, and returns risk cat-
egory based on these values. The RSF object itself is also freely
downloadable as an R [31] object from the same site.4. Discussion
In this study, we have developed and implemented an RSF-
based procedure to classify patients into prognostic categories
based on histomorphological, cytogenetic, and molecular features.
Ours is the first study, to our knowledge, to build and indepen-
dently validate a classifier that initially considers all coding genes
affected by somatic mutations. This is only possible with WES data.
With comprehensive gene mutation data, finding clinically rele-
vant combinations of mutations is highly nontrivial. The RSF struc-
ture enables simultaneous consideration of many genes,
automatically accommodating complex conditional dependencies
between mutation status and patient outcome.
We have deliberately constructed a pan-classifier that is
designed to work across three patient diagnoses. The rationale
for this is that diagnostic categories are somewhat arbitrary (e.g.
thresholds on blast counts) and subjective. Here our risk categories
are predictive across the patient diagnostic subsets, and indeed
compare favorably against MDS-specific schemes. Testing on a lar-
ger independent patient set would be necessary for a more conclu-
sive comparison, however.
Our results shed additional light on the impact of specific genes’
mutations on patient outcome. Integrating mutational information
into the clinical variable-based classifier has the effect of shifting a
subset of patients into different risk categories (Fig. 3). Testing asso-
ciations between the RSF-generated mortality measure and muta-
tional status underscored the impact of gene mutations
previously reported as being myeloid malignancy-related (Supple-
mentary Fig. S11; Supplementary Table S2). Among these, mutation
of TP53 is a well-established indicator of poor outcome [16,15,2].
The same holds true for FLT3 mutations, particularly for patients
with a normal karyotype [7]. DNMT3A mutations have been linked
to poor survival in AML [34,32] andMDS [36], as have RUNX1muta-
tions [2]. Mutations in EZH2 were first reported in MDS/MPN asbeing associated with poor outcome [6]. On the other hand, we
found that SF3B1 mutation was associated with more positive
patient outcome, which has previously been reported [27,12] in
myeloid malignancy.
The study presented here does have some limitations. First, we
only consider the presence or absence of amutation, and donot con-
sider clonal abundance. A recent study reported that the impact of a
mutation on patient outcome does not depend upon its allelic abun-
dance [28]. Therefore, the dichotomous approach may be optimal.
Second, we are treating all non-synonymous mutations equally
and do not consider their differential impacts on protein as mea-
sured by various bioinformatics tools [42,43]. We are also disre-
garding synonymous and non-coding region mutations, which can
have function impact. Third, our sample size is smaller relative to
some recent myeloid malignancy classification studies. The results
presented here should be validated and improved using larger
cohorts. Finally, as mentioned above, the nature of RSFs limits the
ability to gain biological insight from their output. Nonetheless,
we have shown that the RSF results may be used to identify genes
whosemutations specificallymodify the effects of clinical variables.
We view the approach presented here as a general framework to
incorporate WES data into prognostic systems for cancer patients.
Applied to gene-specific mutation data, the RSF can be used to
agnostically identify relevant patient subgroups from cancer of
any type. Although routine whole-exome sequencing on patients
is currently prohibitively expensive for most centers, precipitous
cost decreaseswill make such sequencing feasible in the near future
[23]. Furthermore, mutation-based classification has the advantage
of being less subjective than morphology-based criteria [8]. The
framework proposed here could also be adapted to other complex
tumor genome data such as non-coding RNA, DNA methylation,
and histone modification. Ongoing research efforts will make large
genomic data sets increasingly publicly available, improving the
community’s ability to accurately determine the impact of genomic
features on clinical outcomes. As genomic data becomes ubiquitous
and more complex, correspondingly complex prognostic schemes
like the one presented here may be the wave of the future. One
may envision a direct link between a patient’s electronic medical
record and software to compute a more accurate predicted out-
come. Already, collaborations between IBM and U.S. cancer centers
are underway to train a highly sophisticated computer system,
using vast amounts of patient data, to inform clinical decision mak-
ing (IBM Watson Oncology [40]). In that spirit, accompanying this
study is a web tool implementing our classification software.
Achieving the highest degree of prognostic precisionwill ultimately
rely on optimal use of multiple sources of patient-specific data.Translational relevance
Currently, prognostic schemes that are in clinical use for mye-
loid malignancies suffer from heterogeneity within classes and
poor distinction between classes. Since these schemes are based
on morphological and cytogenetic features, we sought to deter-
mine whether improvement could be gained by including gene-
specific mutation information. Large-scale incorporation of muta-
tional data has only recently become feasible because of advances
in DNA sequencing technology. We proceeded by training a
mutation-based risk classifier on a large set of myeloid malignancy
patients, and validating its accuracy on an independent cohort.
Improved prognostic accuracy would serve to better guide treat-
ment choices. Indeed, patients that are placed into a favorable risk
class with a high degree of confidence could avoid unnecessary
hazard associated with certain treatments. Additionally, individu-
als solidly in a high-risk category may benefit from more experi-
mental treatments.
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